Roche Just Beat the KRAS Kings at Their Own Game

Preclinical data told a similar story. Divarasib is reportedly 5 to 20 times more potent than first-generation KRAS G12C inhibitors in lab settings. The drug was designed from the ground up to bind more tightly and shut down the target more completely.

But cross-trial comparisons are like comparing SAT scores from different test dates; useful as a signal, unreliable as proof. The only way to settle the debate was to run a head-to-head trial. So Roche did exactly that.

The Trial That Changes Everything (Almost)

KRASCENDO-1 randomized patients to receive either divarasib or their doctor's choice of Lumakras or Krazati. The result: statistically significant improvements in both PFS and OS for divarasib. Roche hasn't released the exact numbers yet (those are expected at a major oncology congress), but the direction is clear.

On safety, Roche reported no new safety signals, with adverse events consistent with earlier studies. That's important context because divarasib's Phase 1 profile was already notably clean. Most side effects were low-grade nausea, diarrhea, and fatigue.

Roche's Chief Medical Officer, Levi Garraway, stated the data "confirms the potential of divarasib to improve clinical outcomes" and "should establish divarasib as a new standard of care."

Wall Street Says: Nice, But Show Us First-Line

Roche shares climbed about 3–4% on the news. A solid pop, but not euphoria. Why the measured reaction?

Because analysts are thinking about the bigger prize. Jefferies analyst Michael Leuchten called KRASCENDO-1 "a small win for Roche" and noted it's premature to declare overall victory. His reasoning: the second-line KRAS G12C market (where these patients sit) could generate CHF 1–2 billion in peak sales. That's real money. But the first-line market, where Roche is running a separate trial called KRASCENDO-2, could be worth significantly more.

KRASCENDO-2 is testing divarasib combined with Merck's blockbuster Keytruda against the current standard of Keytruda plus chemotherapy in newly diagnosed patients. If that trial works, divarasib wouldn't just steal share from Lumakras and Krazati; it would intercept patients before they ever need those drugs.

That's the real game-changer. KRASCENDO-1 is the appetizer.

What This Means for Amgen and BMS

Neither company should be panicking yet, but the alarm clock is ringing. Lumakras generated roughly $331 million in 2024 global sales. Krazati brought in $126 million in 2024, growing to $205 million in 2025.

Divarasib won't hit the market overnight. Roche has indicated a regulatory filing around 2027 for second-line NSCLC, which means Lumakras and Krazati have at least another year or two as the only approved options. But once divarasib gets a label, the head-to-head data will be hard to argue with. Oncologists love clear, randomized evidence. Guidelines committees love it even more.

Amgen's best defense may lie in colorectal cancer, where it's running a Phase 3 trial combining sotorasib with its own anti-EGFR antibody, Vectibix. BMS could lean into adagrasib's potential CNS penetration for patients with brain metastases. Both companies also have combination strategies that could differentiate their drugs in ways monotherapy data can't capture.

The KRAS G12C Arms Race Is Just Getting Started

Roche isn't the only one gunning for the throne. Eli Lilly's olomorasib earned an FDA Breakthrough Therapy designation in September 2025 for use with Keytruda in PD-L1-high KRAS G12C NSCLC, posting response rates ranging from 57–74% in early combination data depending on the patient population. Merck's calderasib (MK-1084) is also advancing. D3 Bio is developing Elisrasib, a brain-penetrant G12C inhibitor designed specifically for patients with CNS disease.

The field is evolving from "can we hit this target?" to "how hard can we hit it, and in what combinations?" Triplet regimens (KRAS inhibitor plus immunotherapy plus chemo) are being tested across multiple companies. Anti-resistance strategies involving SHP2 inhibitors, ERK blockers, and even pan-RAS compounds are filling out the pipeline.

For patients with KRAS G12C lung cancer, this competition is unequivocally good news. Five years ago, there was nothing. Now there's an arms race to build the best possible treatment.

For investors, the calculus is more nuanced. KRASCENDO-1 validates Roche's KRAS strategy and strengthens the oncology pipeline story. But the stock's trajectory will ultimately depend on KRASCENDO-2 and whether divarasib can conquer first-line treatment. That's where the billions live.

Roche just proved it can beat the incumbents. The question now: can it beat the standard of care?

Wall Street's Biggest Names Just Bet $1 Billion on One Biotech

Sixth Street and KKR just injected $1 billion of preferred equity into BridgeBio Pharma, one of the largest such deals ever for a public biotech. The unusual structure reveals a new financing playbook for late-stage drug companies caught between clinical success and commercial scale.